The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
Open accessAbstract
BACKGROUND Chemoimmunotherapy is typically the standard of care for patients with Waldenström macroglobulinemia; however, infectious and hematologic toxic effects are problematic. Acalabrutinib is a selective, potent Bruton tyrosine-kinase inhibitor. The aim of this trial was to evaluate the activity and safety of acalabrutinib in patients with Waldenström macroglobulinemia. METHODS This single-arm, multicentre, phase 2 trial was done in 19 European academic centres in France, Italy, Greece, the Netherlands, and the UK, and eight academic centres in the USA. Eligible patients were 18 years or older and had treatment naive (declined or not eligible for chemoimmunotherapy) or relapsed or refractory (at least one previous therapy) Waldenström macroglobulinemia that required treatment, an Eastern Cooperative Oncology Group performance status of 2 or less, and received no previous Bruton tyrosine-kinase inhibitor therapy. Patients received 100 mg oral acalabrutinib twice per day in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed overall response (at least a minor response) according to the 6th International Workshop for Waldenström Macroglobulinemia (IWWM) and the modified 3rd IWWM workshop criteria. The primary outcome and safety were assessed in all patients who received at least one dose of treatment. This study is registered with ClinicalTrials.gov, number NCT02180724, and is ongoing, but no longer enrolling. FINDINGS Between Sept 8, 2014, and Dec 24, 2015, 122 patients were assessed for eligibility, of which 106 (87%) patients were given acalabrutinib (14 were treatment naive and 92 had relapsed or refractory disease). With a median follow-up of 27·4 months (IQR 26·0-29·7), 13 (93% [95% CI 66-100]) of 14 treatment naive patients achieved an overall response and 86 (93% [86-98]) of 92 relapsed or refractory patients per both the modified 3rd and 6th IWWM criteria. Seven (50%) of 14 treatment naive patients and 23 (25%) of 92 relapsed or refractory patients discontinued treatment on study. Grade 3-4 adverse events occurring in more than 5% of patients were neutropenia (17 [16%] of 106 patients) and pneumonia (7 [7%]). Grade 3-4 atrial fibrillation occurred in one (1%) patient and grade 3-4 bleeding occurred in three (3%) patients. The most common serious adverse events were lower respiratory tract infection (n=7 [7%]), pneumonia (n=7 [7%]), pyrexia (n=4 [4%]), cellulitis (n=3 [3%]), fall (n=3 [3%]), and sepsis (n=3 [3%]). Pneumonia (n=5 [5%]) and lower respiratory tract infection (n=4 [4%]) were considered treatment related. One treatment-related death was reported (intracranial hematoma). INTERPRETATION This study provides evidence that acalabrutinib is active as single-agent therapy with a manageable safety profile in patients with treatment-naive, or relapse or refractory Waldenström macroglobulinemia. Further studies are needed to establish its efficacy against current standard treatments and to investigate whether outcomes can be improved with combination therapies. FUNDING Acerta Pharma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33108-2 · Cited by 453
Cited by
Tam, C. S., Opat, S., D'Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Marlton, P., Wahlin, B. E., Sanz, R. G., et al. (2020) · Blood · doi:10.1182/blood.2020006844 · Cited by 466
Self-citationComparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñán, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 267
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Wen, T., Wang, J., Shi, Y., Qian, H., & Liu, P. (2021) · Leukemia · doi:10.1038/s41375-020-01072-6 · Cited by 262
Metadata
- Authors
- Owen, R. G., McCarthy, H., Rule, S., D'Sa, S., Thomas, S. K., Tournilhac, O., Forconi, F., Kersten, M. J., Zinzani, P. L., Iyengar, S., Kothari, J., Minnema, M. C., Kastritis, E., Aurran-Schleinitz, T., Cheson, B. D., Walter, H., Greenwald, D., Chen, D.-Y., Frigault, M. M., Hamdy, A., Izumi, R., Patel, P., Wei, H., Lee, S. K., Mittag, D., & Furman, R. R.
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 7
- Issue
- 2
- Pages
- e112-e121
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W2995503228
- Cited by
- 167
- References
- 1
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. https://app.cochat.ai/papers/10.1016/s2352-3026(19)30210-8
- The paper
- Owen, R. G., McCarthy, H., Rule, S., D'Sa, S., Thomas, S. K., Tournilhac, O., Forconi, F., Kersten, M. J., Zinzani, P. L., Iyengar, S., Kothari, J., Minnema, M. C., Kastritis, E., Aurran-Schleinitz, T., Cheson, B. D., Walter, H., Greenwald, D., Chen, D.-Y., Frigault, M. M., . . . Furman, R. R. (2020). Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(19)30210-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.